Interferon alfa in the treatment of chronic viral hepatitis B and C

Annals of Pharmacotherapy

Volumn 31, Issue 3, 1997, Pages 330-337

  Woo, Michael H ^a,b   Burnakis, Thomas G ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b BAPTIST MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON;

CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FLU LIKE SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT INDICATION;

EID: 0031042035     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809703100312     Document Type: Review

References (59)

1. Margolis HS, Alter MI, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 1991;11:84-92.
2. Pappas SC, Hoofnagle JH, Young N, Straus SE, Jones EA. Treatment of chronic non-A, non-B hepatitis with acyclovir: pilot study. J Med Virol 1985;15:1-9.
3. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
4. Di Bisceglie AM, Hoofnagle JH. Antiviral therapy of chronic viral hepatitis. Am J Gastroenterol 1990;85:650-4.
5. Peters M. Mechanisms of action of interferons. Semin Liver Dis 1989;9:235-9.
6. Baron S, Tyring SK, Fleischmann WR Jr, Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375-83.
7. Henco K, Brosius J, Fujisawa A, Fujisawa J-I, Haynes JR, Hochstadt J, et al. Structural relationship of human Interferon alpha genes and pseudogenes. J Mol Biol 1985;185:227-60.
8. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha Interferon. Semin Liver Dis 1989;9:259-63.
9. Spiegel RJ. Alpha interferons: a clinical overview. Urology 1989;34 (suppl):75-9.
10. Hoofnagle JH, Alter HJ. Chronic viral hepatitis. In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 1984:97-113.
11. Centers for Disease Control and Prevention. CDC hepatitis surveillance report. No. 56 Atlanta: Public Health Service, 1996 (Apr).
12. Hoofnagle JH. Chronic hepatitis B. N Engl J Med 1990;323:337-9.
13. Bernier RH, Sampliner R, Gerety R, Tabor E, Hamilton F, Nathanson N. Hepatitis B infection in households of chronic carriers of hepatitis B surface antigen. Factors associated with prevalence of infection. Am J Epidemiol 1982;116:199-211.
14. Hoofnagle JH, Seeff LB. Natural history of chronic type B hepatitis. Prog Liver Dis 1982;7:469-79.
15. Sampliner RE, Hamilton FA, Iseri OA, Tabor E, Boitnott J. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci 1979;277:17-22.
16. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987;7:758-63.
17. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of Interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
18. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989;10:761-3.
19. Rakela J, Wood JR, Czaja AJ, O'Brien PC, Taswell HF, Bowyer BA, et al. Long-term versus short-term treatment with recombinant interferon alfa-2a in patients with chronic hepatitis B: a prospective, randomized treatment trial. Mayo Clin Proc 1990;65:1330-5.
20. Perrillo RP, Regenstein FG, Peters MG, DeSchryver-Kecskemeti K, Bodicky CJ, Campbell CR, et al. Prednisone withdrawal followed by recombinant alpha interferon in the treatment of chronic type B hepatitis. A randomized, controlled trial. Ann Intern Med 1988;109:95-100.
21. Novick DM, Lok ASF, Thomas HC. Diminished responsiveness of homosexual men to antiviral therapy for HBsAg-positive chronic liver disease. J Hepatol 1984;1:29-35.
22. Roonbloom LE, Alm GV, Oberg KE. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann Intern Med 1991;115:178-83.
23. Scullard GH, Pollard RB, Smith JL, Sacks SL, Gregory PB, Robinson WS, et al. Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside. J Infect Dis 1981;143:772-83.
24. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-92.
25. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie AM, et al. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology 1988;95:1318-25.
26. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the longterm treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
27. Kuhns MC, McNamara AL, Perrillo RP, Cabal CM, Campbell CR. Quantitation of hepatitis B viral DNA by solution hybridization: comparison with DNA polymerase and hepatitis B e antigen during antiviral therapy. J Med Viral 1989;27:274-81.
28. Brook MG, Petrovic L, McDonald JA, Scheuer PJ, Thomas HC. Histological improvement after anti-viral treatment for chronic hepatitis B virus infection. J Hepatol 1989;8:218-25.
29. Di Bisceglie AM, Waggoner JG, Hoofnagle JH. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after viral therapy. Gastroenterology 1987;93:1236-41.
30. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991;114:629-34.
31. Perrillo RP, Brunt EM. Hepatic histologic and immunohistochemical changes in chronic hepatitis B after prolonged clearance of hepatitis B e antigen and hepatitis B surface antigen. Ann Intern Med 1991;115:113-5.
32. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989;244:362-4.
33. Donahue JG, Muñoz A, Ness PM, Brown DE Jr, Yawn DH, McAllister HA Jr, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
34. Zeldis JB, Depner TA, Kuramoto IK, Gish RG, Holland PV. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med 1990;112:958-60.
35. Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, et al. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med 1991;115:367-9.
36. König V, Bauditz J, Lobeck H, Lüsebrink R, Neuhaus P, Blumhardt G, et al. Hepatitis C virus reinfection in allografts after orthotopic liver transplantation. Hepatology 1992;16:1137-43.
37. Wejstal R, Widell A, Mansson AS, Hermodsson S, Norkrans G. Mother-to-infant transmission of hepatitis C virus. Ann Intern Med 1992;117:887-90.
38. Alter MI, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
39. Dienstag JL. Non-A, non-B hepatitis: evolving epidemiologic and clinical perspective. Semin Liver Dis 1986;6:67-81.
40. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis, and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
41. Di Bisceglie AM, Hoofnagle JH, Krawczynski I. Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology 1993;105:858-62.
42. Haber MM, West AB, Haber AD, Reuben A. Relationship of aminotransferases to liver histological status in chronic hepatitis C. Am J Gastroenterol 1995;90:1250-7.
43. Hagiwara H, Hayashi N, Mita E, Takehara T, Kasahara A, Fusamoto H, et al. Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 1993;104:877-83.
44. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long term follow up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-6.
45. van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994;344:1475-9.
46. Camma C, Craxi A, Tine F, Almasio P, Di Marco V, Lo lacono O, et al. Predictors of response to alpha-interferon (IFN) in chronic hepatitis C: a multivariate analysis on 361 treated patients (abstract). Hepatology 1992;16:131A.
47. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
48. Shindo M, Di Bisceglie AM, Cheung L, Shin W-K, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis G viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991;115:700-4.
49. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggonner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
50. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology 1992;15:37-41.
51. Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-alpha in patients with chronic hepatitis C. J Infect Dis 1993;167:780-1.
52. Omata M, Ito Y, Yokosuka O, Imazeki F, Tagawa M, Takano S, et al. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis. Dig Dis Sci 1991;36:1217-22.
53. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-8.
54. Pago T, Marcellin P, Bernau P, Durand F, Poynard T, Benhamou JP. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992;116:51-3.
55. Conlon KC, Urba WJ, Smith JW II, Steis RG, Longo DL, Clark JW. Exacerbation of symptoms of autoimmune disease in patients receiving alpha-interferon therapy. Cancer 1990;65:2237-42.
56. Renault PF, Hoofnagle JH, Park Y, Mullen KD, Peters M, Jones DB, et al. Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-80.
57. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989;9:273-7.
58. Marcellin P, Pouteau M, Renard P, Grynblat J-M, Linhart NC, Bardet P, et al. Sustained hypothyroidism induced by recombinant interferon in patients with chronic hepatitis C. Gut 1992;33:855-6.
59. Antonelli G, Currenti M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 1991;163:882-5.